Response of malignant thymoma to erlotinib

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 19; no. 7; pp. 1361 - 1362
Main Authors Christodoulou, C., Murray, S., Dahabreh, J., Petraki, K., Nikolakopoulou, A., Mavri, A., Skarlos, D.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2008
Oxford University Press
Oxford Publishing Limited (England)
Subjects
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Cetuximab
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Epidermal Growth Factor - genetics
Epidermal Growth Factor - metabolism
Erlotinib Hydrochloride
Fatal Outcome
Gefitinib
Humans
Immunohistochemistry
Protein Kinase Inhibitors - therapeutic use
Quinazolines - therapeutic use
Thymoma - drug therapy
Online AccessGet full text

Cover

More Information
Bibliography:istex:01EBAE778139E428D87A81CAA709BBD0FA43A763
ark:/67375/HXZ-QK0BV98C-L
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdn388